Dissemin is shutting down on January 1st, 2025

Published in

Wiley, Liver International, 2(44), p. 279-285, 2023

DOI: 10.1111/liv.15777

Links

Tools

Export citation

Search in Google Scholar

The role of HBIG in real life for patients undergoing liver transplantation due to HDV‐related cirrhosis

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

AbstractRecommended post‐liver transplant (LT) prophylaxis in patients with hepatitis delta includes a nucleos(t)ide analogue (NA) and anti‐hepatitis B immunoglobulin (HBIG) indefinitely. We analysed the use of HBIG in real‐life clinical practice and its impact on HBV/HDV recurrence in 174 HDV‐related LT patients from 10 Spanish liver transplant centres (1988–2018). Median post‐LT follow‐up was 7.8 (2.3–15.1) years and patient survival at 5 years was 90%. Most patients (97%) received HBIG in the immediate post‐LT, but only 42% were on HBIG at the last control. Among those discontinuing HBIG, the median time on treatment was 18 (7–52) months. Post‐LT HBsAg+ was detected in 16 (9%) patients and HBV‐DNA in 12 (7%). Despite HBsAg positivity, HDV recurrence was reported only in three patients (1.7%), all of whom were not receiving NA and had discontinued HBIG. Our data suggest that a finite HBIG prophylaxis in HDV‐LT is feasible, especially if high‐barrier NAs are used.